Dyslipidaemia: The PCSK9 adventure - humanizing extreme LDL lowering

Nat Rev Cardiol. 2017 Jun;14(6):319-320. doi: 10.1038/nrcardio.2017.66. Epub 2017 May 4.
No abstract available

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Antibodies, Monoclonal / pharmacology
  • Anticholesteremic Agents / pharmacology
  • Cardiovascular Diseases / prevention & control*
  • Cholesterol, LDL / blood
  • Clinical Trials as Topic
  • Dyslipidemias* / blood
  • Dyslipidemias* / drug therapy
  • Dyslipidemias* / genetics
  • Humans
  • PCSK9 Inhibitors
  • Pharmacogenetics
  • Proprotein Convertase 9* / genetics

Substances

  • Antibodies, Monoclonal
  • Anticholesteremic Agents
  • Cholesterol, LDL
  • PCSK9 Inhibitors
  • PCSK9 protein, human
  • Proprotein Convertase 9